PDE IV Inhibitors
1 drugsAbout PDE IV
Phosphodiesterase IV (PDE IV) regulates intracellular levels of cyclic adenosine monophosphate (cAMP), a key signaling molecule involved in various cellular processes. By breaking down cAMP, PDE IV influences a wide range of physiological functions.
PDE IV's involvement in inflammatory pathways makes it a potential drug target, particularly in respiratory diseases. However, there is currently no genetic evidence directly linking PDE IV to specific diseases.
One FDA-approved drug, THEO-24, targets PDE IV as a small molecule for respiratory indications. ENDO OPERATIONS is the only company with an approved PDE IV drug.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Triple-negative Breast Cancer with only 1 trials.
Top PDE IV Drugs
ENDO OPERATIONS is the only company with an approved drug targeting PDE IV.
Low competition may indicate high barriers to entry or limited market potential.
PDE IV Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PDE IV, using small molecule modality.
The absence of other modalities suggests a whitespace opportunity for novel approaches.
PDE IV Clinical Trials 38 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 8 | 5 | 2 | 1 | 71% |
| Phase 2 | 14 | 10 | 0 | 3 | 100% |
| Phase 3 | 3 | 3 | 0 | 0 | 100% |
| Phase 4 | 13 | 11 | 1 | 1 | 92% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
PDE IV Drug Approval Timeline (1983 - 1983)
The first and most recent drug approval for PDE IV was THEO-24 in 1983.
The lack of recent approvals suggests a saturated market or challenges in developing new PDE IV inhibitors.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 24 clinical trials targeting PDE IV.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities